Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective

  • Urology - Review
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Androgen deprivation therapy (ADT) plays an important role in managing prostate cancer. However, ADT may result in major cardiovascular events and potentially lead to fatal consequences. Cardiovascular disease is the leading cause of mortality and it is a very important health condition to look into. Asians and Caucasians differ both physiologically and genetically, and they may have display different cardiovascular profiles. In this article, we reviewed the literature focusing on the cardiovascular risk after ADT for prostate cancer in the Asian population. We would discuss about the pathogenesis of ADT leading to cardiovascular events, summarize the findings concerning cardiac and stroke risks after ADT, compare between the different modalities of ADT and also provide genetic basics which are unique to Asians. We hope this article would provide more insights into the cardiovascular risk after ADT for prostate cancer in an Asian perspective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Huggins C, Hodges CV (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168:9–12

    Article  PubMed  Google Scholar 

  2. Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G et al (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472–479

    Article  CAS  PubMed  Google Scholar 

  3. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–106

    Article  CAS  PubMed  Google Scholar 

  4. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G et al (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295–300

    Article  CAS  PubMed  Google Scholar 

  5. D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292:821–827

    Article  PubMed  Google Scholar 

  6. Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294:238–244

    Article  CAS  PubMed  Google Scholar 

  7. Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154–179

    Article  PubMed  Google Scholar 

  8. Keating NL, O’Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448–4456

    Article  CAS  PubMed  Google Scholar 

  9. Lage MJ, Barber BL, Markus RA (2007) Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer. Urology 70:1104–1108

    Article  CAS  PubMed  Google Scholar 

  10. Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA (2005) Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int 16:707–711

    Article  CAS  PubMed  Google Scholar 

  11. Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S (2011) Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 60:1244–1250

    Article  CAS  PubMed  Google Scholar 

  12. Ohira T, Iso H (2013) Cardiovascular disease epidemiology in Asia: an overview. Circ J 77:1646–1652

    Article  PubMed  Google Scholar 

  13. Collins L, Mohammed N, Ahmad T, Basaria S (2012) Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care. J Endocrinol Invest 35:332–339

    CAS  PubMed  Google Scholar 

  14. Saylor PJ, Smith MR (2009) Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 181:1998–2006 (discussion 7–8)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Traish AM, Saad F, Guay A (2009) The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 30:23–32

    Article  CAS  PubMed  Google Scholar 

  16. Scragg JL, Jones RD, Channer KS, Jones TH, Peers C (2004) Testosterone is a potent inhibitor of L-type Ca(2+) channels. Biochem Biophys Res Commun 318:503–506

    Article  CAS  PubMed  Google Scholar 

  17. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH et al (2004) Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 90:871–876

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Dong F, Skinner DC, Wu TJ, Ren J (2011) The heart: a novel gonadotrophin-releasing hormone target. J Neuroendocrinol 23:456–463

    Article  CAS  PubMed  Google Scholar 

  19. Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A et al (2010) Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 363:1621–1630

    Article  CAS  PubMed  Google Scholar 

  20. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65:565–573

    Article  CAS  PubMed  Google Scholar 

  21. Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS et al (2015) Risk of acute myocardial infarction after androgen-deprivation therapy for prostate cancer in a Chinese population. BJU Int 116:382–387

    Article  CAS  PubMed  Google Scholar 

  22. Teoh JY, Chiu PK, Chan SY, Mak VM, Poon DM, Cheung HY et al (2016) Androgen deprivation therapy and the risk of acute myocardial infarction in Chinese men with prostate cancer. BJU Int 117(Suppl 1):2

    Google Scholar 

  23. Huang G, Yeung CY, Lee KK, Liu J, Ho KL, Yiu MK et al (2014) Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate. J Oncol 2014:529468

    Article  PubMed  PubMed Central  Google Scholar 

  24. Akaza H (2010) Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology 85:110–120

    Article  CAS  PubMed  Google Scholar 

  25. Wang LH, Liu CK, Chen CH, Kao LT, Lin HC, Huang CY (2016) No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese/Taiwanese men. Andrology 4:128–132

    Article  CAS  PubMed  Google Scholar 

  26. Teoh JY, Chiu PK, Chan SY, Poon DM, Cheung HY, Hou SS et al (2015) Risk of ischemic stroke after androgen deprivation therapy for prostate cancer in the Chinese population living in Hong Kong. Jpn J Clin Oncol 45:483–487

    Article  PubMed  Google Scholar 

  27. Chung SD, Chen YK, Wu FJ, Lin HC (2012) Hormone therapy for prostate cancer and the risk of stroke: a 5-year follow-up study. BJU Int 109:1001–1005

    Article  CAS  PubMed  Google Scholar 

  28. Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A et al (2010) Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol 28:3448–3456

    Article  PubMed  Google Scholar 

  29. Jespersen CG, Norgaard M, Borre M (2014) Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol 65:704–709

    Article  CAS  PubMed  Google Scholar 

  30. Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102:39–46

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD et al (2014) The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study. BJU Int 114:E82–E89

    Article  CAS  PubMed  Google Scholar 

  32. Teoh JY, Chan SY, Chiu PK, Poon DM, Cheung HY, Hou SS et al (2015) Risk of cardiovascular thrombotic events after surgical castration versus gonadotropin-releasing hormone agonists in Chinese men with prostate cancer. Asian J Androl 17:493–496

    CAS  PubMed  Google Scholar 

  33. Zaitsu M, Yamanoi M, Mikami K, Takeshima Y, Okamoto N, Imao S et al (2012) Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration. Adv Urol 2012:979154

    Article  PubMed  Google Scholar 

  34. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P et al (2008) The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102:1531–1538

    Article  CAS  PubMed  Google Scholar 

  35. Ozono S, Ueda T, Hoshi S, Yamaguchi A, Maeda H, Fukuyama Y et al (2012) The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer. Jpn J Clin Oncol 42:477–484

    Article  PubMed  Google Scholar 

  36. You D, Chung BH, Lee SE, Kim CS (2015) Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study. Prostate Int 3:22–26

    Article  PubMed  PubMed Central  Google Scholar 

  37. Li J, Mercer E, Gou X, Lu YJ (2013) Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes. Am J Cancer Res 3:127–151

    PubMed  PubMed Central  Google Scholar 

  38. Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL et al (2000) Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res 60:5111–5116

    CAS  PubMed  Google Scholar 

  39. Stanford JL, Just JJ, Gibbs M, Wicklund KG, Neal CL, Blumenstein BA et al (1997) Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 57:1194–1198

    CAS  PubMed  Google Scholar 

  40. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A et al (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 94:3320–3323

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Mohlig M, Arafat AM, Osterhoff MA, Isken F, Weickert MO, Spranger J et al (2011) Androgen receptor CAG repeat length polymorphism modifies the impact of testosterone on insulin sensitivity in men. Eur J Endocrinol 164:1013–1018

    Article  PubMed  Google Scholar 

  42. Nadeau G, Bellemare J, Audet-Walsh E, Flageole C, Huang SP, Bao BY et al (2011) Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer. J Clin Endocrinol Metab 96:E1550–E1557

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. SH Ho Urology Centre, Division of Urology, Department of Surgery, 4/F LCW Clinical Science Building, Prince of Wales Hospital, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, New Territories, Hong Kong, China

    Jeremy Yuen Chun Teoh & Chi-Fai Ng

Authors
  1. Jeremy Yuen Chun Teoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chi-Fai Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chi-Fai Ng.

Ethics declarations

Conflict of interest

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teoh, J.Y.C., Ng, CF. Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective. Int Urol Nephrol 48, 1429–1435 (2016). https://doi.org/10.1007/s11255-016-1337-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-016-1337-5

Keywords

Search

Navigation